Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

CAFC upholds patent term extensions in Levaquin and Metvixia cases: Ortho-McNeil and Daiichi Sankyo v. Lupin; Photocure v. Kappos (Orange Book Blog) (SPC blog) (FDA Law Blog)

Circadin (Melatonin) – UK: EWHC upholds refusal of SPC: Neurim Pharmaceuticals (1991) Limited v. Comptroller-General of Patents (EPLAW) (IP Factor) (SPC blog)

Border detention of counterfeit and/or ‘counterfeit’ pharma products – ‘Free Trade of Pharmaceutical Products: The Limits of Intellectual Property Enforcement at the Border’ paper by Xavier Seuba (IPKat)

Deloitte white paper points to recession as turning point for life sciences industry; indicates that survival will depend on innovation (Patent Docs)

WIPO Traditional Knowledge Committee opens with hope for text-based talks (IP Watch)

New WHO documents show results on IP, innovation, technology transfer (IP Watch)

WIPO traditional knowledge committee moving toward legal agreement (IP Watch) (IP Watch)

Canada: New directions for biotech infringement remedies (Jeremy de Beer)

Dominican Republic: A prescription for failure: Health and IP in the Dominican Republic (IP Watch)

India: Parliament misses opportunity to discuss ‘data exclusivity’ for agro-chemicals (Spicy IP)

Indian Official: ACTA out of sync with TRIPs and Public Health (IP Watch)

Japan: Revised Japanese examination guidelines for medical inventions (Patent Baristas)

Mexico: The Mexican Supreme Court expands the linkage system to prevent patent infringement: (Relat IP)

Nigeria: ‘Economic sabotage’ claim as NAFDAC destroys fakes (Afro-IP)

South Africa: South Africa taps patent pool for neglected diseases (Patently BIOtech)

US: Blown 30-month ANDA tentative approval and approval dates – A growing industry concern; Is litigation in the works? (FDA Law Blog)

US: Divisional of a divisional: Avoid terminal disclaimers: CAFC denies en banc rehearing in Boehringer Ingelheim International GMBH v. Barr Laboratories, Inc. (Patently-O)

US: Patent provisions of U.S. health-care reform legislation (Ladas & Parry)

US: Ariad (2010) and the overlooked invention priority principle (Patently-O)

US Policy leaders discuss U.S. innovation economy at BIO-AUTM technology transfer symposium (Patently BIOtech)

US: IP Watchdog Blog: ‘In search of technology transfer best practices’ (Patently BIOtech)

Scientific American Worldview 2010: Measuring global biotechnology innovation and rollout (Biotech Blog) (Biotech Blog)

US: Schering seeks review and correction of the patent term adjustment calculation for patent covering ‘methods for inhibiting sterol absorption’: Schering Corp. et al. v. Kappos (Patent Docs)

US: Pieczenik files suits over alleged infringement of patent covering ‘method and means for sorting and identifying biological information’: Pieczenik v. Astellaspharma, Inc. et al.; Pieczenik v. Bayer Corp. et al. (Patent Docs)

Alavert (Loratadine) – US: TTAB vacates WAL-VERT decision per District Court order: Wyeth v Walgreen Co (not precedential) (TTABlog)

Axid (Nizatidine), Synthanthic (Oxfendazole) – US: False marking complaint: Baker v. Pfizer, Inc. et al. (Patent Docs)

Circadin (Melatonin) – UK: EWHC upholds refusal of SPC: Neurim Pharmaceuticals (1991) Limited v. Comptroller-General of Patents (EPLAW) (IP Factor) (SPC blog)

Duetact (Pioglitazone and Glimepiride) – US: Infringement of patent following a Paragraph IV certification: Takeda Pharmaceutical Co. Ltd. et al. v. Sandoz, Inc. (Patent Docs)

Evista (Raloxifene) – US: Patent infringement complaint following a Paragraph IV certification: Eli Lilly & Company v. Watson Pharmaceuticals, Inc. et al. (Patent Docs)

Levaquin (Levofloxacin) – US: CAFC upholds patent term extensions in Levaquin and Metvixia cases: Ortho-McNeil and Daiichi Sankyo v. Lupin; Photocure v. Kappos (Orange Book Blog) (SPC Blog) (FDA Law Blog)

Lexapro (Escitalopram) – Denmark: H. Lundbeck A/S v. Pharma Change ApS – Actavis A/S entered as independent party (EPLAW)

Metvixia (Methyl aminolevulinate) – US: CAFC upholds patent term extensions in Levaquin and Metvixia cases: Ortho-McNeil and Daiichi Sankyo v. Lupin; Photocure v. Kappos (Orange Book Blog) (FDA Law Blog)

OxyContin (Oxycodone) – US: Patent infringement suit following a Paragraph IV certification: Purdue Pharma L.P. et al v. Ranbaxy Inc. et al. (Patent Docs)

Protonix (Pantoprazole) – US: Jury upholds validity of Pfizer’s Protonix patent (Patent Docs)

Ritalin (Methylphenidate) – US: Celgene and Novartis reach settlement with Barr Laboratories in Ritalin ANDA Suit (Patent Docs)

Seasonale (Ethinyl estradiol, Levonorgestrel) – US: Watson reaches settlement with Teva over Seasonale (SmartBrief)

Simcor(Simvastatin, Niacin) – US:Patent infringement complaint following a Paragraph IV certification: Abbott Laboratories et al v. Watson Pharmaceuticals Inc. et al. (Patent Docs)

Valcyte (Valganciclovir) – India overturns patent on AIDS patient drug (IP Watch)

Viread (Tenofovir) – India: Cipla serves legal notice on GWU; demands a written apology for events in relation to the GWU-CII Summit (Spicy IP)

Zetia (Ezetimibe) – US: Three claims of Schering’s Zetia patent found invalid(Patent Docs)